References
- Huang Y, Yang C, Xu X F, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–1149.
- Chavda VP, Vora LK, Pandya AK, et al. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today [Internet]. 2021; https://doi.org/10.1016/j.drudis.2021.07.021
- Lu R, Zhao X, Li J, et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 395(10224): 565–574. 2020.
- Wang M-Y, Zhao R, Gao L-J, et al. SARS-CoV-2: structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol [Internet]. 2020;10:724.
- Wang N, Shang J, Jiang S, et al. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298.
- Snijder EJ, Decroly E, Ziebuhr J. The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv Virus Res. 2016;96:59–126.
- Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236.
- Romano M, Ruggiero A, Squeglia F, et al. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells [Internet]. 2020;9:1267. 1267:
- Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128. [Internet]. ;:. Available from
- V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–170.Internet]. ;:. Available from
- Kumar S, Nyodu R, Maurya VK, et al. Host immune response and immunobiology of human SARS-CoV-2 infection. Saxena SKeditor. Coronavirus Dis 2019 Epidemiol Pathog Diagnosis, Ther [Internet]. 2020;43–53. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189399/
- Wang Y, Wang Y, Chen Y, et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568–576.
- Darif D, Hammi I, Kihel A, et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog [Internet]. 2021;153:104799.
- Chavda VP, Apostolopoulos V. Mucormycosis – an opportunistic infection in the aged immunocompromised individual: a reason for concern in COVID-19. Maturitas [Internet]. 2021; https://doi.org/10.1016/j.maturitas.2021.07.009
- Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432.
- Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108. Xi’an Jiaotong University.
- The Promise AJ and Peril of antibody testing for COVID-19.JAMA.2020;323(19):1881–1883; [Internet]. ;:. Available from
- Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(281–292.e6):281–292.e6.
- Tang F, Quan Y, Xin Z-T, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186(12):7264–7268.
- Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. [Internet]. 2014 August 18. 2014;111:12283–12287. Available from. ;(34):. https://pubmed.ncbi.nlm.nih.gov/25136134
- Baxby D. Edward Jenner’s inquiry after 200 years. BMJ. 1999;318(7180):390.
- Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol. 2011;9(12):889–893. England.
- Hawken J, Troy SB. Adjuvants and inactivated polio vaccine: a systematic review. Vaccine. [Internet]. 2012 October 03. 2012;30:6971–6979. Available from. ;(49):. https://pubmed.ncbi.nlm.nih.gov/23041122
- Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis.2014;210(suppl_1):S439–S446; [Internet]. ;:. Available from
- Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201–12215.
- Chavda VP, Vora LK, Dr V. COVAX-19Ⓡ vaccine: completely blocks virus transmission to non-immune individuals. Clin Complement Med Pharmacol [Internet]. 2021;1:100004. 1.
- Batty CJ, Heise MT, Bachelder EM, et al. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev. 2021;169:168–189.
- Parkins K. Covaxin: india’s homegrown Covid-19 vaccine brings hope and controversy [Internet]. 2021 [ cited 2021 Jun 1]. p. Last Updated 2021 Apr 27th. Available from: https://www.clinicaltrialsarena.com/analysis/covaxin-indias-homegrown-covid-19-vaccine-brings-hope-and-controversy/.
- Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–594. [Internet]. ;:. Available from
- Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479-480:379–392.
- Kaur SP, Gupta VCOVID-19. Vaccine: a comprehensive status report. Virus Res. [Internet]. 2020 August 13. 2020;288:198114. Available from. [];:. : https://pubmed.ncbi.nlm.nih.gov/32800805.
- Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963.
- McGill COVID19 vaccine tracker team. VACCINES CANDIDATES BY TRIAL PHASE [Internet]. 2021 [cited 2021 Aug 21]. p. Last Updated 2021 Aug 20. Available from: https://covid19.trackvaccines.org/vaccines/.
- Jones I, Sputnik RP. V COVID-19 vaccine candidate appears safe and effective. Lancet.2021;397(10275):642–643;Internet]. ;:. Available from
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
- Hofman K, Shenoy GN, Chak V, et al. Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines. Immunol Invest [Internet]. 2021;1–37. Available from. ;. https://doi.org/10.1080/08820139.2021.1904977
- Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824–1835.
- Carl Zimmer, Jonathan Corum, and Sui-Lee, Wee Coronavirus Vaccine Tracker . The New York Times. 2021 12 10 2021 https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
- Burki T. Understanding variants of SARS-CoV-2. Lancet.2021;397(10273):462;Internet]. ;:. Available from
- Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants — clinical, public health, and vaccine implications. N Engl J Med.2021;384(19):1866–1868; [Internet]. ;:. Available from
- Chua BY, Sekiya T, Jackson DC. Opinion: making inactivated and subunit-based vaccines work. Viral Immunol. 2018;31(2):150–158.
- Qian C, Liu X, Xu Q, et al. Recent progress on the versatility of virus-like particles. Vaccines (Basel) [Internet]. 2020 [ cited 2021 Apr 27];8:139. 1
- Medicago. Medicago and gsk start phase 3 trial of adjuvanted COVID-19 vaccine candidate [Internet]. March 16, 2021. 2021 [cited 2021 Apr 10]. Available from: https://www.medicago.com/en/media-room/medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/
- Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601.
- De Nmgp Q, Marinho FV, Chagas MA, et al. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. Microbes Infect. 2020;22(10):515–524.
- Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14–20.
- Yoo JH. What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci. [Internet]. 2021;36:e54–e54. ;(6)
- Panicali D, Davis SW, Weinberg RL, et al. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci [Internet]. 1983;80:5364–5368. 17
- Nakano E, Panicali D, Paoletti E. Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A. [Internet]. 1982;79:1593–1596. (5):
- Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A. 1982;79(16):4927–4931.
- Son H-Y, Apostolopoulos V, Chung J-K, et al. Protective efficacy of a plasmid DNA vaccine against transgene-specific tumors by Th1 cellular immune responses after intradermal injection. Cell Immunol [Internet]. 2018;329:17–26.
- Seo YB, Suh YS, Ryu JI, et al. Soluble spike DNA vaccine provides long-term protective immunity against SARS-CoV-2 in mice and nonhuman primates. Vaccines (Basel). 2021;9(4):307.
- Ferraro B, Morrow MP, Hutnick NA, et al. Clinical applications of DNA vaccines: current progress. Clin Infect Dis [Internet]. 2011;53:296–302. 3
- Lopes A, Vandermeulen G, Cancer PV. DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res.2019;38(1):146;Internet]. ;:. Available from
- Apostolopoulos V, Weiner DB. Development of more efficient and effective DNA vaccines. Expert Rev Vaccines.2009;8(9):1133–1134; [Internet]. ;:. Available from
- Khan KH. DNA vaccines: roles against diseases. Germs. Internet]. 2013;3:26–35. (1):
- Lewis PJ, Babiuk LA. DNA vaccines: a review. Adv Virus Res. 1999;54:129–188.
- Braathen R, HCL S, Hinke DM, et al. A DNA vaccine that encodes an antigen-presenting cell-specific heterodimeric protein protects against cancer and influenza. Mol Ther - Methods Clin Dev [Internet]. 2020;17:378–392.
- Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–788.
- Løvås T-O, Bruusgaard JC, Øynebråten I. Løvås T-O, Bruusgaard JC, Øynebråten I, et al. DNA vaccines: MHC II-targeted vaccine protein produced by transfected muscle fibres induces a local inflammatory cell infiltrate in mice. SadeghNasseri S, editor. . SadeghNasseri S, editor. PLoS One [Internet]. 2014 [cited 2021 Jun 1;9:e108069. 10
- Williams JA, Carnes AE, Hodgson CP. Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv. [Internet]. 2009 2009 February 20;27:353–370.
- Dong Y, Dai T, Wei Y, et al. OPEN A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1). https://doi.org/10.1038/s41392-020-00352-y.
- Silveira MM, Moreira GMSG, Mendonça M. DNA vaccines against COVID-19: perspectives and challenges. Life Sci [Internet]. 2020 December 19. 2021;267:118919.
- Eschenburg G, Stermann A, Preer R, et al. DNA Vaccination: using the Patient’s Immune System to Overcome Cancer. Rezaei N, editor. Clin Dev Immunol [Internet]. 2010; 2010:169484. Available from https://doi.org/10.1155/2010/169484
- Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. [Internet]. 2013;4:114. Available from. ;:. https://pubmed.ncbi.nlm.nih.gov/23720661
- Wennhold K, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. B cell-based cancer immunotherapy. Transfus Med Hemother. [Internet]. 2019;46:36–46. (1)
- Li -D-D, Q-h L. SARS-CoV-2: vaccines in the pandemic era. Mil Med Res. 2021;8(1). https://doi.org/10.1186/s40779-020-00296-y [Internet]. ;:. Available from
- Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: immunological Mechanism and Beyond. Vaccines (Basel). [Internet]. 2021;9:147. (2):
- Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel). Internet]. 2019;7:37. (2):
- Prompetchara E, Ketloy C, Tharakhet K, et al. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS One. 2021;16(3):e0248007. [Internet]. ;:. Available from
- Li H, Yang Y, Hong W, et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. [Internet]. 2020;5:1. Available from. ;(): https://doi.org/10.1038/s41392-019-0089-y.
- Flingai S, Czerwonko M, Goodman J, et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol [Internet]. 2013;4:354.
- Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines [Internet]. 2015 December 28. 2015;15:313–329. 3
- Bolhassani A, Yazdi SR. DNA immunization as an efficient strategy for vaccination. Avicenna J Med Biotechnol [Internet]. 2009;1:71–88. Available fromhttps://pubmed.ncbi.nlm.nih.gov/23407787
- Barolet D, Benohanian A. Current trends in needle-free jet injection: an update. Clin Cosmet Investig Dermatol [Internet]. 2018;11:231–238. Available fromhttps://pubmed.ncbi.nlm.nih.gov/29750049
- Ravi AD, Sadhna D, Nagpaal D, et al. Needle free injection technology: a complete insight. Int J Pharm Investig Internet]. 2015;5:192–199. 4
- Brocato RL, Kwilas SA, Josleyn MD, et al. Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines. bioRxiv [Internet]. 2020;2020 November 09.374439. Available from. ; :. http://biorxiv.org/content/early/2020/11/09/2020.11.09.374439.abstract
- Sokołowska E, Au B-Z. A critical review of electroporation as a plasmid delivery system in mouse skeletal muscle. Int J Mol Sci. [Internet]. 2019;20:2776. (11):
- Gao Y, Wijewardhana C, Mann JFS, et al. Liposome, and polymeric particle-based vaccines against HIV-1. Front Immunol. [Internet]. 2018;9:345. Available from. ;:. https://pubmed.ncbi.nlm.nih.gov/29541072
- Ak G, Rath G, Garg T. Nanotechnological approaches for genetic immunization. Erdmann VA, Barciszewski J, editors. DNA RNA Nanobiotechnologies Med Diagnosis Treat Dis [Internet]. 2013;67–120. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121080/
- Farris E, Brown DM, Ramer-Tait AE, et al. Micro- and nanoparticulates for DNA vaccine delivery. Exp Biol Med (Maywood). [Internet]. 2016 April 04. 2016;241:919–929. 9:
- Liu C, Zhang L, Zhu W, et al. Barriers and strategies of cationic liposomes for cancer gene therapy. Mol Ther Methods Clin Dev [Internet]. 2020;18:751–764.
- Wang N, Chen M, Wang T. Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization. J Control Release [Internet]. 2019 May 03. 2019;303:130–150.
- Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. [Internet]. 2015;10:975–999. Available from. ;:. https://pubmed.ncbi.nlm.nih.gov/25678787
- Wang F-Y, Chen Y, Huang -Y-Y, et al. Transdermal drug delivery systems for fighting common viral infectious diseases. Drug Deliv Transl Res. 2021;11(4):1498–1508. [Internet]. ; Available from
- Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. J Control Release [Internet]. 2015 November 18. 2016;240:135–141.
- Yang B, Jeang J, Yang A, et al. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother [Internet]. 2014;10:3153–3164. 11
- Hasson SSAA, JKZ A-B, Sallam TA. The past, current and future trends in DNA vaccine immunisations. Asian Pac J Trop Biomed. [Internet]. 2015;5:344–353. (5):
- Hobernik D, Bros M. DNA vaccines-how far from clinical use? Int J Mol Sci. [Internet]. 2018;19:3605. (11):
- Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239(1):62–84.
- Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev [Internet]. 2017 April 22. 2017;114:116–131.
- Dey A, Chozhavel Rajanathan TM, Chandra H, et al. Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. bioRxiv [Internet]. 2021;2021 January 26.428240. Available from http://biorxiv.org/content/early/2021/01/26/2021.01.26.428240.abstract
- Momin T, Kansagra K, Patel H, et al. Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine [Internet]. 2021;38. https://doi.org/10.1016/j.eclinm.2021.101020.
- Cadila Healthcare Ltd. Zydus Cadila receives approvals from the DCGI to start Phase III Clinical Trial of ZyCoV-D – fully indigenously developed vaccine [Internet]. 2021 [ cited 2021 Jun 1]. 03 January, 2021. Available from: https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_receives_approvals_from_the_DCGI_to_start_Phase_III_Clinical_Trial_of_ZyCoV_D_fully_indigenously_developed_vaccine_-3_1_2021.pdf.
- Cadila Healthcare Ltd. Zydus Cadila submits Phase I/II clinical trial data of ZyCoV-D, seeks nod to start Phase III Clinical Trials [Internet]. 2020 [ cited 2021 Jun 1]. December 24, 2020. Available from: https://www.google.com/search?q=https%3A%2F%2Fzyduscadila.com%2Fpublic%2Fpdf%2Fpressrelease%2FZydus_Cadila_submits_Phase_II_clinical_trial_data_of_ZyCoV_D_seeks_nod_to_start_Phase_III_Clinical_Trials_24_12_2020.pdf+&rlz=1C1CHBD_enIN909IN909&sxsrf=ALeKk03R.
- Mammen MP, Tebas P, Agnes J, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv [Internet]. 2021;2021 May 07.21256652. Available from. ; :. http://medrxiv.org/content/early/2021/05/07/2021.05.07.21256652.abstract
- Tebas P, Yang SP, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2021;31:1–9.
- Staff R. Japan’s AnGes begins phase 2/3 clinical trial of DNA-based COVID-19 vaccine [Internet]. Healthc. PHARMA. 2021 [ cited 2021 Jun 1]. Available from: https://www.reuters.com/article/us-anges-covid-vaccine-idUSKBN28I0EA.
- Conforti A, Marra E, Palombo F, et al. COVID-<em>e</em>Vax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19. bioRxiv [Internet]. 2021;2021 June 14.448343. Available from. ; :. http://biorxiv.org/content/early/2021/06/14/2021.06.14.448343.abstract
- Algazi AP, Twitty CG, Tsai KK, et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res an off J Am Assoc Cancer Res. 2020;26(12):2827–2837.
- Samrat SK, Tharappel AM, Li Z, et al. Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development. Virus Res Internet]. 2020 August 23. 2020;288:198141.
- Motamedi H, Ari MM, Dashtbin S, et al. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. Int Immunopharmacol [Internet]. 2021 May 06. 2021;96:107763.
- Pushparajah D, Jimenez S, Wong S, et al. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Deliv Rev [Internet]. 2021 January 07. 2021;170:113–141. Available from. ; :. https://pubmed.ncbi.nlm.nih.gov/33422546
- Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. [Internet]. 2011 April 27. 2011;23:421–429. Available from. ;(3):. https://pubmed.ncbi.nlm.nih.gov/21530212
- Young JL, Dean DA. Electroporation-mediated gene delivery. Adv Genet. Internet]. 2014 December 11. 2015;89:49–88. Available from; :. :https://pubmed.ncbi.nlm.nih.gov/25620008
- Richardson J. INOVIO planning for ex-US global phase 3 trial for INO-4800 [Internet]. 2021 [ cited 2021 Jun 1]. p. Updated on 2021 Apr 23. Available from: https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Planning-for-ex-US-Global-Phase-3-Trial-for-INO-4800/default.aspx.
- Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021;892:173751.
- Carlson R, Reiter D, Lutmer H. AG0301 COVID-19 vaccine [Internet]. precisionvaccinations. 2021 cited 2021 Jun 1. p. Updated April 22, 2021. Available from https://www.precisionvaccinations.com/vaccines/ag0301-covid-19-vaccine
- Howlett SE, Castillo HS, Gioeni LJ, et al. Evaluation of DNAstable for DNA storage at ambient temperature. Forensic Sci Int Genet. 2014;8(1):170–178.
- Singh S. India gives emergency approval for world’s first COVID-19 DNA vaccine [Internet]. Ed. by Shounak Dasgupta Maju Samuel. 2021 [cited 2021 Aug 21]. p. August 20, 2021. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/india-approves-zydus-cadilas-covid-19-vaccine-emergency-use-2021-08-20/. ears safe and effective Available from: https://doi.org/10.1016/j.eclinm.2021.101020.